Diffusion Pharmaceuticals Inc.

0.7070+0.0120+1.73%Vol 2.95M1Y Perf 51.53%
Apr 16th, 2021 16:00 DELAYED
BID0.7100 ASK0.7175
Open0.6600 Previous Close0.6950
Pre-Market- After-Market-
 - -  - -%
Target Price
2.00 
Analyst Rating
Strong Buy 1.00
Potential %
182.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap72.05M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
21.11 
Earnings Date
10th May 2021

Today's Price Range

0.63000.7238

52W Range

0.40121.85

5 Year PE Ratio Range

-0.6000-0.6000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-16.13%
1 Month
-34.54%
3 Months
-37.43%
6 Months
-16.17%
1 Year
51.53%
3 Years
-92.01%
5 Years
-99.53%
10 Years
-99.99%

TickerPriceChg.Chg.%
DFFN0.70700.01201.73
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.06-0.060.00
Q03 2020-0.06-0.07-16.67
Q02 2020-0.06-0.10-66.67
Q01 2020-0.09-0.0722.22
Q03 2019-0.71-0.6015.49
Q02 2019-0.69-0.638.70
Q01 2019-0.91-0.8110.99
Q03 2018-0.90-0.7516.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0516.67Positive
6/2021 QR-0.0433.33Positive
12/2021 FY-0.1818.18Positive
12/2022 FY-0.1821.74Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.05
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.95M
Shares Outstanding101.90M
Trades Count5.55K
Dollar Volume10.86M
Avg. Volume7.26M
Avg. Weekly Volume2.05M
Avg. Monthly Volume2.19M
Avg. Quarterly Volume7.61M

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) stock closed at 0.707 per share at the end of the most recent trading day (a 1.73% change compared to the prior day closing price) with a volume of 2.96M shares and market capitalization of 72.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Diffusion Pharmaceuticals Inc. CEO is Robert Joseph Cobuzzi.

The one-year performance of Diffusion Pharmaceuticals Inc. stock is 51.53%, while year-to-date (YTD) performance is -11.07%. DFFN stock has a five-year performance of -99.53%. Its 52-week range is between 0.4012 and 1.85, which gives DFFN stock a 52-week price range ratio of 21.11%

Diffusion Pharmaceuticals Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 3.65, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.78%, a ROC of -74.15% and a ROE of -69.05%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Diffusion Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Diffusion Pharmaceuticals Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Diffusion Pharmaceuticals Inc. is Strong Buy (1), with a target price of $2, which is +182.89% compared to the current price. The earnings rating for Diffusion Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Diffusion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Diffusion Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.39, ATR14 : 0.13, CCI20 : -173.24, Chaikin Money Flow : -0.09, MACD : -0.13, Money Flow Index : 18.77, ROC : -18.77, RSI : 37.36, STOCH (14,3) : 25.67, STOCH RSI : 0.15, UO : 40.16, Williams %R : -74.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Diffusion Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer.

CEO: Robert Joseph Cobuzzi

Telephone: +1 434 220-0718

Address: 1317 Carlton Avenue, Charlottesville 22902, VA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

News

Stocktwits